BR9707637A - Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico - Google Patents

Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico

Info

Publication number
BR9707637A
BR9707637A BR9707637A BR9707637A BR9707637A BR 9707637 A BR9707637 A BR 9707637A BR 9707637 A BR9707637 A BR 9707637A BR 9707637 A BR9707637 A BR 9707637A BR 9707637 A BR9707637 A BR 9707637A
Authority
BR
Brazil
Prior art keywords
subcutaneous
implant system
local administration
system intended
implantable implant
Prior art date
Application number
BR9707637A
Other languages
English (en)
Inventor
Saleh Ismail Saleh
Alfred J Moo-Young
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Publication of BR9707637A publication Critical patent/BR9707637A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Prostheses (AREA)
  • Coupling Device And Connection With Printed Circuit (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR9707637A 1996-02-23 1997-02-21 Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico BR9707637A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/606,063 US5733565A (en) 1996-02-23 1996-02-23 Male contraceptive implant
PCT/US1997/002798 WO1997030656A1 (en) 1996-02-23 1997-02-21 Male contraceptive implant

Publications (1)

Publication Number Publication Date
BR9707637A true BR9707637A (pt) 1999-07-27

Family

ID=24426375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707637A BR9707637A (pt) 1996-02-23 1997-02-21 Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico

Country Status (12)

Country Link
US (1) US5733565A (pt)
EP (2) EP1488784B1 (pt)
JP (1) JP2000505419A (pt)
AT (2) ATE344018T1 (pt)
AU (1) AU1969697A (pt)
BR (1) BR9707637A (pt)
CA (1) CA2243274C (pt)
DE (2) DE69736911T2 (pt)
DK (2) DK1488784T3 (pt)
ES (2) ES2274367T3 (pt)
PT (2) PT1488784E (pt)
WO (1) WO1997030656A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US5952319A (en) 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
NZ331201A (en) * 1998-07-30 2001-02-23 Bomac Lab Ltd Slow release implants comprising an insoluble polymeric material in the form of a porous network containing vitamin B12 dispersed within
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
FR2842421B1 (fr) * 2002-07-16 2004-10-15 Besins Int Belgique Nouvelles compositions pharmaceutiques a base d'inhibiteurs de la 5-alpha-reductase et leurs utilisations
WO2004016083A1 (ja) * 2002-08-19 2004-02-26 Nagoya Industrial Science Research Institute 球脊髄性筋萎縮症の病態を再現する非ヒト動物、及び球脊髄性筋萎縮症治療剤
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20060093639A1 (en) * 2004-10-29 2006-05-04 Starkebaum Warren L Method and device for destroying body tissue
AU2006259368A1 (en) 2005-06-15 2006-12-28 Hydra Biosciences, Inc. Modulators of sperm hypermotility and uses thereof
PL2547332T3 (pl) 2010-03-16 2019-07-31 Titan Pharmaceuticals, Inc. Heterogeniczne wyroby wszczepialne do podaży leku
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
WO2017027376A1 (en) 2015-08-07 2017-02-16 Massachusetts Institute Of Technology Subcutaneous drug delivery device with manual activation and deactivation of drug release
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
EP4100075A4 (en) 2020-03-20 2024-01-31 The Regents of University of California IMPLANTABLE DRUG RELEASE DEVICES FOR LOCALIZED DRUG RELEASE
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4451253A (en) * 1980-12-18 1984-05-29 Harman Sherman M Means and method for administering medicinals
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device

Also Published As

Publication number Publication date
DK0881891T3 (da) 2005-05-23
DE69732176D1 (de) 2005-02-10
JP2000505419A (ja) 2000-05-09
ES2236793T3 (es) 2005-07-16
ES2274367T3 (es) 2007-05-16
ATE344018T1 (de) 2006-11-15
WO1997030656A1 (en) 1997-08-28
EP1488784A1 (en) 2004-12-22
EP0881891A1 (en) 1998-12-09
ATE286370T1 (de) 2005-01-15
PT881891E (pt) 2005-04-29
US5733565A (en) 1998-03-31
DE69736911D1 (de) 2006-12-14
DK1488784T3 (da) 2007-03-05
PT1488784E (pt) 2006-12-29
DE69736911T2 (de) 2007-06-14
EP0881891A4 (en) 2000-02-02
EP1488784B1 (en) 2006-11-02
CA2243274C (en) 2003-07-22
DE69732176T2 (de) 2006-05-11
CA2243274A1 (en) 1997-08-28
EP0881891B1 (en) 2005-01-05
AU1969697A (en) 1997-09-10

Similar Documents

Publication Publication Date Title
DK0881891T3 (da) Mandigt præventionsimplantat
NO923769D0 (no) System for iontoforetisk tilfoersel av et medikament
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
ATE370764T1 (de) Vorrichtung zur lokalen verabreichung von fest- oder halbfesten pharmazeutischen zusammensetzungen
DE59610355D1 (de) Medizinisches implantat
MD1432C2 (ro) Metodă de tratament al stării dependente de estrogenii ovarieni
ES2007100A6 (es) Procedimiento para la obtencion de un sistema terapeutico oral a base de carbamazepina.
BR9902528A (pt) Sistema implantável e implante destinado à administração subcutânea ou local
NO964864L (no) Orale, flytende alendronatpreparater
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
AU6251094A (en) Bisacodyl dosage form
JP2002500180A5 (pt)
DE69332758D1 (de) Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
WO1996020732A3 (en) Non-traumatic administration of gene delivery vehicles
GB2328872B (en) Method for preparing pharmaceutical formulations
AU3401093A (en) Therapeutic agent for threatened abortion
ATE223726T1 (de) Formulierung zur peptidfreisetzung
EP0365613A4 (en) Combination of tobramycin and steroids for topical ophthalmic use
EP0811385A3 (en) Conjugate of a factor specifically recognizing interleukin-2 receptor with ribonuclease
Rosen Results of mobilization of fixed stapedial foot plate in otosclerotic deafness
DK561989A (da) Fokalt ophthalmisk praeparat som indeholder en kombination af tobramycin og steroider
NO984725L (no) Depot-antiprogestin-behandling
UA29005A (uk) Спосіб лікування трофічних виразок нижніх кінцівок

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 11 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]